Dimitrios Panidis, Konstantinos Tziomalos, Efstathios Papadakis, Ilias Katsikis
Index: Front. Horm. Res. 40 , 128-41, (2013)
Full Text: HTML
Management of patients with polycystic ovary syndrome (PCOS) who wish to become pregnant should include exclusion of other diseases in the woman and additional fertility disorders in the couple. Before the initiation of any pharmacological intervention, the importance of lifestyle modifications should be stressed, particularly weight loss, increased exercise, smoking cessation and reduced alcohol consumption. The pharmacological treatment of choice for the induction of ovulation and for achieving live birth is the combination of metformin and clomiphene citrate. If this combination is unsuccessful, second-line treatments include the administration of gonadotropins and laparoscopic ovarian drilling. Induction of ovulation using clomiphene or gonadotropins leads to single live birth in 72% of cases, whereas laparoscopic ovarian drilling leads to live birth in 50% of cases. In vitro fertilization represents third-line treatment. Finally, individualized interventions can be implemented for the induction of ovulation depending on the specific characteristics of patients with PCOS. These interventions might deviate from the above-designated order of treatments in specific subgroups of patients with PCOS. Copyright © 2013 S. Karger AG, Basel.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Enclomiphene hydrochloride
CAS:14158-65-7 |
C26H29Cl2NO |
Bone Mineral Density and Response to Treatment in Men Younge...
2014-04-01 [J. Urol. 191(4) , 1072-6, (2014)] |
Progesterone luteal support after ovulation induction and in...
2013-11-01 [Fertil. Steril. 100(5) , 1373-80, (2013)] |
Re: Optimization of Spermatogenesis-Regulating Hormones in P...
2013-12-01 [J. Urol. 190(6) , 2209, (2013)] |
Evaluation of the genotoxicity of clomiphene citrate.
2014-01-01 [Mutat. Res. Genet. Toxicol. Environ. Mutagen. 759 , 21-7, (2014)] |
Insulin sensitizers in polycystic ovary syndrome.
2013-01-01 [Front. Horm. Res. 40 , 83-102, (2013)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved